Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
Authors' conclusion
Normoglycemia was unprecedently achieved in a significant proportion of participants in the SURPASS clinical program, without increasing hypoglycemia risk, and was associated with an overall improvement in metabolic health.
Study context
- Population
- Tirzepatide-treated participants in SURPASS 1–4 taking ≥75% of treatment doses, without rescue medicationSURPASS 1–4
- Participants
- 3,229 participants
- Comparison
- Tirzepatide-treated participants by HbA1c attainment category at week 40
- Outcome
- Characteristics and changes in participants achieving HbA1c <5.7%
- Follow-up
- Week 40
Methodological detailsdescriptive statistics, logistic regression adjusted for tirzepatide dose
- Descriptive statistics
- Logistic regression adjusted for tirzepatide dose
Pooled result
As reported in the abstract
week 40
- Those achieving HbA1c <5.7% were slightly younger, with shorter diabetes duration and lower baseline HbA1c vs those who did not
- Greater improvements in HbA1c, body weight, waist circumference, blood pressure, liver enzymes and lipid parameters
- Exploratory analysis
Safety
- No increase in hypoglycemia risk with HbA1c <5.7%
Original publication
Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials. Diabetes Care. Published 6 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →